Volition logo logo
Cancer cells
Capture_seq_logo

A breakthrough in detecting cancer DNA in blood.

Capture-Seq™

Overview

Capture-Seq™

Potential to revolutionize cancer detection

Volition has developed Capture-Seq™, a novel liquid biopsy method to isolate pure circulating tumor-derived DNA (ctDNA) from blood, generating sequencing datasets with significantly higher tumor signal.

This is the world’s first isolation of transcription factor-DNA and the first preparation of pure ctDNA sequence data sets.

Volition has compelling clinical data from a blinded validation proof-of-concept study.

Capture-Seq™ correctly identified 93% of cancers (colorectal and lung cancer; n=59).

In hard-to-detect early-stage cancer, the platform correctly identified 94% of stage I and 96% of stage II cancers.

volition-veterinarians-2
Hear from our team

Watch the Volition team share exciting updates about the Capture-SeqTM technology and its potential to improve patient outcomes through multi-cancer detection, disease monitoring and tumor naïve testing for minimal residual disease (MRD).

cap seq study
Our Solution

Cancer signals are lost in the noise of blood

 

Blood contains DNA fragments from across the body:

  • >99% from healthy cells
  • <1% tumor-derived in early-stage disease

Current approaches:

  • Analyze nucleosomal DNA (130–200 bp)
  • Search for mutations within this background

Limitation:

Tumor signal is diluted and often undetectable, particularly in early disease.

Volition Belgium Day 1 - June 20220663_High_res

From invisible to actionable

In a methodological world first, Volition has developed a novel liquid biopsy method designed to isolate and analyze pure circulating tumor-derived DNA (ctDNA) from blood samples.

 

Metric

Result
Background cfDNA removed >99.7%
CTCF-DNA enrichment ~180×
Target DNA recovery ~48%
Output Highly enriched tumor-derived DNA
volition-card-1

Our technology in action

Landscape

Watch: A deeper dive into Capture-Seq™

In this film, Dr Jake Micallef explains how Capture-SeqTM isolates ultrashort transcription-factor-bound DNA fragments, enabling the analysis of highly enriched tumor DNA from a simple blood sample.

volition-placeholder
Capture-Seq™ a breakthrough in detecting cancer in DNA blood
Landscape4

Capture-Seq™ is being explored for several major clinical uses with the goal of improving patient outcomes.

We believe this represents a significant commercial opportunity, with a Total Addressable Market on an annualized basis of approximately:

$23 billion for human multi-cancer early detection

>$13 billion in testing for MRD

volition-card-2

Next Steps

Partnership opportunities.

 

Volition is actively exploring licensing and development partnerships to accelerate the clinical development and commercialization of Capture-Seq™.

The technology may complement existing liquid biopsy platforms and diagnostic technologies.

For partnership enquiries please contact: mediarelations@volition.com

Volition